The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Stephen M. Ansell

Division of Hematology

Mayo Clinic

Rochester

Minnesota

[email]@mayo.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota. 2011 - 2012
  • Mayo Clinic, Division of Hematology, 200 First Street SW, Rochester, USA. 2002 - 2011
  • Division of Hematology, Mayo Clinic, Rochester, Minnesota and North Central Cancer Treatment Group, USA. 2006

References

  1. Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management. Ansell, S.M. Am. J. Hematol. (2012) [Pubmed]
  2. Annual clinical updates in hematological malignancies: A continuing medical education series. Hodgkin lymphoma: 2011 update on diagnosis, risk-stratification, and management. Ansell, S.M. Am. J. Hematol. (2011) [Pubmed]
  3. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Ansell, S.M., Tang, H., Kurtin, P.J., Koenig, P.A., Inwards, D.J., Shah, K., Ziesmer, S.C., Feldman, A.L., Rao, R., Gupta, M., Erlichman, C., Witzig, T.E. Lancet Oncol. (2011) [Pubmed]
  4. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells. Ansell, S.M. Expert. Opin. Investig. Drugs (2011) [Pubmed]
  5. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Ansell, S.M., Kyle, R.A., Reeder, C.B., Fonseca, R., Mikhael, J.R., Morice, W.G., Bergsagel, P.L., Buadi, F.K., Colgan, J.P., Dingli, D., Dispenzieri, A., Greipp, P.R., Habermann, T.M., Hayman, S.R., Inwards, D.J., Johnston, P.B., Kumar, S.K., Lacy, M.Q., Lust, J.A., Markovic, S.N., Micallef, I.N., Nowakowski, G.S., Porrata, L.F., Roy, V., Russell, S.J., Short, K.E., Stewart, A.K., Thompson, C.A., Witzig, T.E., Zeldenrust, S.R., Dalton, R.J., Rajkumar, S.V., Gertz, M.A. Mayo Clin. Proc. (2010) [Pubmed]
  6. Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma. Ansell, S.M., Novak, A.J., Ziesmer, S., Price-Troska, T., LaPlant, B., Dillon, S.R., Witzig, T.E. Am. J. Hematol. (2009) [Pubmed]
  7. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Ansell, S.M., Hurvitz, S.A., Koenig, P.A., LaPlant, B.R., Kabat, B.F., Fernando, D., Habermann, T.M., Inwards, D.J., Verma, M., Yamada, R., Erlichman, C., Lowy, I., Timmerman, J.M. Clin. Cancer Res. (2009) [Pubmed]
  8. Phase I clinical study of atacicept in patients with relapsed and refractory B-cell non-Hodgkin's lymphoma. Ansell, S.M., Witzig, T.E., Inwards, D.J., Porrata, L.F., Ythier, A., Ferrande, L., Nestorov, I., Devries, T., Dillon, S.R., Hausman, D., Novak, A.J. Clin. Cancer Res. (2008) [Pubmed]
  9. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. Ansell, S.M., Horwitz, S.M., Engert, A., Khan, K.D., Lin, T., Strair, R., Keler, T., Graziano, R., Blanset, D., Yellin, M., Fischkoff, S., Assad, A., Borchmann, P. J. Clin. Oncol. (2007) [Pubmed]
  10. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients. Ansell, S.M., Geyer, S.M., Maurer, M.J., Kurtin, P.J., Micallef, I.N., Stella, P., Etzell, P., Novak, A.J., Erlichman, C., Witzig, T.E. Clin. Cancer Res. (2006) [Pubmed]
  11. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. Elsawa, S.F., Novak, A.J., Grote, D.M., Ziesmer, S.C., Witzig, T.E., Kyle, R.A., Dillon, S.R., Harder, B., Gross, J.A., Ansell, S.M. Blood (2006) [Pubmed]
  12. Management of Hodgkin lymphoma. Ansell, S.M., Armitage, J.O. Mayo Clin. Proc. (2006) [Pubmed]
  13. Non-Hodgkin lymphoma: diagnosis and treatment. Ansell, S.M., Armitage, J. Mayo Clin. Proc. (2005) [Pubmed]
  14. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Ansell, S.M., Arendt, B.K., Grote, D.M., Jelinek, D.F., Novak, A.J., Wellik, L.E., Remstein, E.D., Bennett, C.F., Fielding, A. Leukemia (2004) [Pubmed]
  15. Antibody therapy for non-Hodgkin's lymphoma. Ansell, S.M. Curr. Opin. Mol. Ther. (2004) [Pubmed]
  16. Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Ansell, S.M., Schilder, R.J., Pieslor, P.C., Gordon, L.I., Emmanouilides, C., Vo, K., Czuczman, M.S., Witzig, T.E., Theuer, C., Molina, A. Clin. Lymphoma (2004) [Pubmed]
  17. Adding cytokines to monoclonal antibody therapy: does the concurrent administration of interleukin-12 add to the efficacy of rituximab in B-cell non-hodgkin lymphoma?. Ansell, S.M. Leuk. Lymphoma (2003) [Pubmed]
  18. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Ansell, S.M., Witzig, T.E., Kurtin, P.J., Sloan, J.A., Jelinek, D.F., Howell, K.G., Markovic, S.N., Habermann, T.M., Klee, G.G., Atherton, P.J., Erlichman, C. Blood (2002) [Pubmed]
  19. Subsequent chemotherapy regimens are well tolerated after radioimmunotherapy with yttrium-90 ibritumomab tiuxetan for non-Hodgkin's lymphoma. Ansell, S.M., Ristow, K.M., Habermann, T.M., Wiseman, G.A., Witzig, T.E. J. Clin. Oncol. (2002) [Pubmed]
 
WikiGenes - Universities